Beyond that, we validated the good prognostic value of ZNF281 in CESC, STAD, and PAAD and finally established risk prediction models based on ZNF281-related molecules for future clinical diagnosis and treatment. This evidence concerns the gene ZNF281 and pancreatic adenocarcinoma.